Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,2035 SEK | -5,57% | -40,12% | -97,96% |
22/04 | Transcript : Xbrane Biopharma AB - Special Call | |
26/02 | Transcript : Xbrane Biopharma AB, 2023 Earnings Call, Feb 26, 2024 |
Omzet 2024 * | 372 mln. 34,24 mln. 32,02 mln. | Omzet 2025 * | 785 mln. 72,22 mln. 67,53 mln. | Marktkapitalisatie | 330 mln. 30,34 mln. 28,37 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -101 mln. -9,3 mln. -8,69 mln. | Nettowinst (verlies) 2025 * | 211 mln. 19,42 mln. 18,16 mln. | EV/omzet 2024 * | 0,51 x |
Nettoliquiditeiten 2024 * | 138 mln. 12,74 mln. 11,91 mln. | Nettoliquiditeiten 2025 * | 21,29 mln. 1,96 mln. 1,83 mln. | EV/omzet 2025 * | 0,39 x |
K/w-verhouding 2024 * |
-2,16
x | K/w-verhouding 2025 * |
0,04
x | Werknemers | 93 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 93,48% |
Recentste transcriptie over Xbrane Biopharma AB
1 dag | -4,87% | ||
1 week | -40,12% | ||
Lopende maand | -32,17% | ||
1 maand | -22,98% | ||
3 maanden | -88,07% | ||
6 maanden | -98,94% | ||
Lopend jaar | -97,96% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Martin Åmark
CEO | Chief Executive Officer | 44 | 01-01-15 |
Anette Lindqvist
DFI | Director of Finance/CFO | 63 | 11-01-21 |
Dina Jurman
CTO | Chief Tech/Sci/R&D Officer | 42 | 09-10-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 67 | 01-01-15 | |
Director/Board Member | 70 | 01-01-15 | |
Director/Board Member | 53 | 01-01-20 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
24-04-24 | 0,2035 | -5,57% | 46 768 905 |
23-04-24 | 0,2155 | -8,30% | 64 018 490 |
22-04-24 | 0,235 | -33,24% | 198 129 300 |
19-04-24 | 0,352 | -3,30% | 20 968 650 |
18-04-24 | 0,364 | +6,59% | 24 708 150 |
uitgestelde koers Nasdaq Stockholm, 24 april 2024 om 16:29 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-97,96% | 30,45 mln. | |
+4,76% | 43,43 mld. | |
+47,98% | 41,69 mld. | |
+10,22% | 41,31 mld. | |
-10,82% | 27,14 mld. | |
+10,00% | 25,28 mld. | |
-24,53% | 18,47 mld. | |
+35,70% | 12,59 mld. | |
+2,72% | 12,33 mld. | |
+8,81% | 11,03 mld. |